The branded drugmaker's $24 a share beat a $22 offer for Obagi Medical Products (OMPI) by Merz Phama, which declined to top Valeant Pharmaceuticals' (VRX) bid. Obagi's stock vaulted 65% while the pair was vying for it, but it slid nearly 6% Monday after Valeant's offer won. Valeant's shares got whacked last week when Mylan (MLY) gained an unexpected approval for a generic version of Valeant's herpes cream Zovirax. Valeant shares rose 0.5% to72.12.
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
"We are not very ambitious. I should be careful about talking about work-life balance, but the Americans just work harder.”
In his 2016 letter to Berkshire Hathaway shareholders, legendary investor Warren Buffett wrote, “Every decade or so, dark clouds will fill the economic skies, and they will briefly rain gold. When downpours of that sort occur, it’s imperative that we ...
These proven wealth builders could be exactly what you're searching for right now.
It's possible to construct a winning long-term investment strategy with just low-cost index funds.
Intel reported its Q1 earnings on Thursday, beating analysts' estimates. But a disappointing outlook sent shares sliding.
As US growth shows signs of sputtering and inflation keeps rising, a re-run of the tumultuous 1970s is looking more likely.
The combination of artificial intelligence (AI) and cybersecurity is a match made in heaven.
Data center equipment spending is being driven by AI-related investment.
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.